Butterfly Network to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21, 2024
Butterfly Network (NYSE: BFLY), a digital health company specializing in handheld ultrasound technology, has announced its participation in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21, 2024, in New York City. CEO Joseph DeVivo and CFO Heather Getz will conduct one-on-one meetings throughout the event. DeVivo will present a business overview at 11:00 am ET. The presentation will be available via webcast on the company's investor website until February 19, 2025.
Butterfly Network (NYSE: BFLY), un'azienda di salute digitale specializzata nella tecnologia degli ultrasuoni portatili, ha annunciato la sua partecipazione al Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum il 21 novembre 2024, a New York. Il CEO Joseph DeVivo e il CFO Heather Getz condurranno incontri individuali durante l'evento. DeVivo presenterà una panoramica aziendale alle 11:00 ET. La presentazione sarà disponibile tramite webcast sul sito degli investitori dell'azienda fino al 19 febbraio 2025.
Butterfly Network (NYSE: BFLY), una empresa de salud digital especializada en tecnología de ultrasonido portátil, ha anunciado su participación en el Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum el 21 de noviembre de 2024 en Nueva York. El CEO Joseph DeVivo y la CFO Heather Getz llevarán a cabo reuniones uno a uno durante el evento. DeVivo presentará una visión general del negocio a las 11:00 am ET. La presentación estará disponible a través de un webcast en el sitio web de inversionistas de la empresa hasta el 19 de febrero de 2025.
버터플라이 네트워크 (NYSE: BFLY)는 휴대용 초음파 기술을 전문으로 하는 디지털 건강 회사로, 2024년 11월 21일 뉴욕에서 열리는 카나콘드 제뉴이티 메드텍, 진단 및 디지털 건강 & 서비스 포럼에 참가한다고 발표했습니다. CEO 조셉 드비보와 CFO 헤더 겟즈는 행사 동안 개별 회의를 진행할 것입니다. 드비보는 동부 표준시로 오전 11시에 사업 개요를 발표할 예정입니다. 발표 내용은 2025년 2월 19일까지 회사의 투자자 웹사이트를 통해 웹캐스트로 제공될 것입니다.
Butterfly Network (NYSE: BFLY), une entreprise de santé numérique spécialisée dans la technologie d'échographie portable, a annoncé sa participation au Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum le 21 novembre 2024 à New York. Le PDG Joseph DeVivo et la directrice financière Heather Getz mèneront des réunions en tête-à-tête tout au long de l'événement. DeVivo présentera un aperçu de l'entreprise à 11h00 ET. La présentation sera disponible en webdiffusion sur le site web des investisseurs de l'entreprise jusqu'au 19 février 2025.
Butterfly Network (NYSE: BFLY), ein digitales Gesundheitsunternehmen, das sich auf tragbare Ultraschalltechnologie spezialisiert hat, hat seine Teilnahme am Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum am 21. November 2024 in New York City angekündigt. CEO Joseph DeVivo und CFO Heather Getz werden während der Veranstaltung Einzelgespräche führen. DeVivo wird um 11:00 Uhr ET eine Unternehmensübersicht präsentieren. Die Präsentation wird bis zum 19. Februar 2025 über einen Webcast auf der Investorenseite des Unternehmens verfügbar sein.
- None.
- None.
Joseph DeVivo, President, Chief Executive Officer & Chairman, and Heather Getz, Executive Vice President & Chief Financial and Operations Officer will host one-on-one meetings throughout the day, and Mr. DeVivo will deliver a business overview presentation at 11:00 am ET.
A webcast of the presentation will be posted to the Events & Presentations section of the Butterfly investor website, and available for replay until February 19, 2025.
To schedule a one-on-one meeting with Mr. DeVivo and Ms. Getz, please reach out to your CG representative.
About Butterfly Network
Founded by Dr. Jonathan Rothberg in 2011, Butterfly Network is a digital health company with a mission to democratize medical imaging by making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Butterfly created the world's first handheld single-probe, whole-body ultrasound system using semiconductor technology, Butterfly iQ. The company has continued to innovate, leveraging the benefits of Moore’s Law, to launch its second generation Butterfly iQ+ in 2020, and third generation iQ3 in 2024 – each with increased processing power and performance enhancements. The disruptive technology has been recognized by TIME’s Best Inventions, Fast Company’s World Changing Ideas, CNBC Disruptor 50, and MedTech Breakthrough Awards, among other accolades. With its proprietary Ultrasound-on-Chip™ technology, intelligent software, and educational offerings, Butterfly is paving the way to mass adoption of ultrasound for earlier detection and remote management of health conditions around the world. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of
View source version on businesswire.com: https://www.businesswire.com/news/home/20241107932509/en/
Butterfly Investors:
Heather Getz
Chief Financial and Operations Officer, Butterfly
investors@butterflynetwork.com
Source: Butterfly Network, Inc.
FAQ
When is Butterfly Network (BFLY) presenting at the Canaccord Genuity Forum?
How long will the Butterfly Network (BFLY) Canaccord presentation webcast be available?
Who will represent Butterfly Network (BFLY) at the Canaccord Genuity Forum?
What type of meetings will Butterfly Network (BFLY) host at the Canaccord Forum?
